How to improve R&D productivity: the pharmaceutical industry's grand challenge

@article{Paul2010HowTI,
  title={How to improve R\&D productivity: the pharmaceutical industry's grand challenge},
  author={Steven M Paul and Daniel S Mytelka and Christopher T. Dunwiddie and Charles C. Persinger and Bernard H. Munos and Stacy R. Lindborg and Aaron Leigh Schacht},
  journal={Nature Reviews Drug Discovery},
  year={2010},
  volume={9},
  pages={203-214}
}
The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines… Expand

Figures and Topics from this paper

Redefining how pharmaceutical innovation gets done
TLDR
This thesis investigates and improves upon a novel financing technique that has been proposed to facilitate the R&D funding in the bio-pharmaceutical industry, and introduces a new financing paradigm to address the issue of high aggregate costs for these highly curative therapies. Expand
Changing R&D models in research-based pharmaceutical companies
TLDR
Research-based pharmaceutical companies need to be aware of the key factors, which impact the rate of innovation, R&D cost and probability of success, as they challenge the model of an innovation-driven pharmaceutical industry. Expand
Drug discovery in pharmaceutical industry: productivity challenges and trends.
  • I. Khanna
  • Biology, Medicine
  • Drug discovery today
  • 2012
TLDR
An emerging 'symbiotic model of innovation', that addresses underlying issues in drug failure and attempts to narrow gaps in current drug discovery processes, is discussed to boost productivity. Expand
The productivity crisis in pharmaceutical R&D
TLDR
This study examines the decline of R&D productivity in pharmaceuticals in the past two decades and shows that this decline is associated with an increasing concentration ofR&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms. Expand
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
TLDR
This work systematically analyze, identify, assess, and categorize key risks across the drug discovery and development value chain using a new risk map approach, providing a comprehensive risk-reward analysis for pharmaceutical R&D. Expand
Big Data in Pharmaceutical R&D: Creating a Sustainable R&D Engine
TLDR
With the implementation of ‘Big Data’ initiatives trying to integrate data from disparate data sources and disciplines that are available in life science, the industry has identified a new frontier that might provide the insights needed to turn the ship around and allow the industry to return to sustainable growth. Expand
The productivity crisis in pharmaceutical R &
| Advances in the understanding of the molecular basis of diseases have expanded the number of plausible therapeutic targets for the development of innovative agents in recent decades. However,Expand
Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis
TLDR
An adaptive trial design with the potential to increase success rates of clinical trials by 4 percentage points could lower development costs for a new drug from 2.6 to 2.2bn USD, which would free up an additional 4.2 billion USD for investment into pharmaceutical R&D to bring about drug innovations. Expand
Trends in Innovation and the Business of Drug Discovery
Pharmaceutical innovation provides medical discoveries that are vital to the quality of healthcare and longevity. Increasing additions to the medical database is a way of providing safer and widerExpand
How to conduct research in the pharmaceutical industry? Facing the dilemma: small, autonomous teams versus large, integrated centers
  • H. Federsel
  • Medicine
  • Expert opinion on drug discovery
  • 2010
TLDR
It is crucial not to adopt a one-size-fits-all approach but rather to address the specific needs in a given setting and design tailor-made solutions that stand a chance of being successful. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
The Value of Improving the Productivity of the Drug Development Process
  • J. DiMasi
  • Business, Medicine
  • PharmacoEconomics
  • 2012
TLDR
Whether faster development times, quicker termination decisions or higher success rates derive from public policy initiatives, better management, or new technologies, the impact on R&D costs can be substantial and result in more innovation and new therapies reaching patients sooner. Expand
Rebuilding the R&D engine in big pharma.
  • J. Garnier
  • Business, Medicine
  • Harvard business review
  • 2008
TLDR
A cultural revolution and a broad transformation of the organization are necessary first steps to rebuilding the R&D engine, the GlaxoSmithKline CEO says. Expand
Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
Using data on over 900 firms for the period 1988-2000, we estimate the effect on phase-specific biotech and pharmaceutical RD the diversification of its experience, and alliances with large and smallExpand
Modeling Resource Requirements for Pharmaceutical R&D
OVERVIEW: The task of bringing novel pharmaceutical products to market quickly at reasonable cost is daunting. While both pharmaceutical sales and R&D expenses are on the rise, the latter isExpand
Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
TLDR
It is found that success probabilities vary substantially across therapeutic categories and are negatively correlated with mean sales by category, which is consistent with a model of dynamic, competitive entry. Expand
Challenge and Opportunity on the Critical Path to New Medical Products
i This report provides the Food and Drug Administration's (FDA's) analysis of the pipeline problem — the recent slowdown, instead of the expected acceleration, in innovative medical therapiesExpand
The cost of biopharmaceutical R&D: is biotech different?
The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However, similar analyses have not been publishedExpand
Science Business: The Promise, the Reality, and the Future of Biotech
Why has the biotechnology industry failed to perform up to expectations--despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of theExpand
Market Watch: Pharma industry performance metrics: 2007–2012E
TLDR
The analysis focuses on each company’s major prescription drug portfolio (MrDP; the collection of branded drugs each of which is projected to achieve at least us$500 million in annual sales) as a key measure of overall performance as well as forecasted metrics from this peer-group analysis. Expand
The State of Innovation in Drug Development
  • I. Kola
  • Medicine
  • Clinical pharmacology and therapeutics
  • 2008
TLDR
Because drug development has been stagnant in terms of innovation, there exists huge potential for innovation and failure to innovate drug development will render the “big pharma” model unsustainable. Expand
...
1
2
3
4
5
...